Should I buy or sell Morphic stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Morphic in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" MORF shares. View MORF analyst ratings or view top-rated stocks .

What is Morphic's stock price target for 2024?

6 analysts have issued 1 year price objectives for Morphic's shares. Their MORF share price targets range from $33.00 to $80.00. On average, they predict the company's stock price to reach $61.00 in the next year. This suggests a possible upside of 117.9% from the stock's current price. View analysts price targets for MORF or view top-rated stocks among Wall Street analysts .

How have MORF shares performed in 2024?

Morphic's stock was trading at $28.88 at the start of the year. Since then, MORF stock has decreased by 3.1% and is now trading at $27.99. View the best growth stocks for 2024 here .

When is Morphic's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 23rd 2024. View our MORF earnings forecast .

How were Morphic's earnings last quarter?

Morphic Holding, Inc. (NASDAQ:MORF) issued its earnings results on Thursday, February, 22nd. The company reported ($0.94) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.89) by $0.05.

What ETFs hold Morphic's stock?

ETFs with the largest weight of Morphic (NASDAQ:MORF) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO) . First Trust Small Cap Growth AlphaDEX Fund (FYC) .

What other stocks do shareholders of Morphic own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Morphic investors own include Fulcrum Therapeutics (FULC) , Akero Therapeutics (AKRO) , AVEO Pharmaceuticals (AVEO) , Atreca (BCEL) , CymaBay Therapeutics (CBAY) , Chiasma (CHMA) , Clovis Oncology (CLVS) , Gritstone bio (GRTS) , Idera Pharmaceuticals (IDRA) and Kaleido Biosciences (KLDO) .

When did Morphic IPO?

Morphic (MORF) raised $75 million in an IPO on Thursday, June 27th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Jefferies, Cowen, BMO Capital Markets and Wells Fargo Securities acted as the underwriters for the IPO.

How do I buy shares of Morphic?

Shares of MORF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:MORF

Morphic (MORF) Stock Price, News & Analysis

→ The A.I. story nobody is telling you (Read ASAP) (From TradeSmith) (Ad)

Free MORF Stock Alerts

$27.99

+0.48 (+1.74%)

(As of 04/19/2024 ET)

Compare

Today's Range: $27.12
▼
$28.16
50-Day Range: $27.51
▼
$40.31
52-Week Range: $19.34
▼
$63.08

Volume: 382,674 shs
Average Volume: 369,248 shs
Market Capitalization: $1.40 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $61.00

Get Morphic alerts:

Morphic MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 117.9% Upside
$61.00 Price Target
Short Interest: Bearish
11.79% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.57
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($3.90) to ($4.26) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.49 out of 5 stars

Medical Sector

267th out of 911 stocks

Pharmaceutical Preparations Industry

108th out of 410 stocks

3.3

Analyst's Opinion

Consensus Rating
Morphic has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Morphic has received no research coverage in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
11.79% of the outstanding shares of Morphic have been sold short.
Short Interest Ratio / Days to Cover
Morphic has a short interest ratio ("days to cover") of 11.4, which indicates bearish sentiment.
Change versus previous month
Short interest in Morphic has recently decreased by 3.91%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Morphic does not currently pay a dividend.
Dividend Growth
Morphic does not have a long track record of dividend growth.

4.8

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Morphic has received a 76.58% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health" and "Clinical research services for physiological diseases " products. See details.
Environmental Sustainability
The Environmental Impact score for Morphic is -0.57.

1.3

News and Social Media Coverage

News Sentiment
Morphic has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Morphic this week, compared to 2 articles on an average week.
MarketBeat Follows
Only 2 people have added Morphic to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Morphic insiders have not sold or bought any company stock.
Percentage Held by Insiders
28.10% of the stock of Morphic is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
94.25% of the stock of Morphic is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Morphic are expected to decrease in the coming year, from ($3.90) to ($4.26) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Morphic is -8.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Morphic is -8.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Morphic has a P/B Ratio of 2.00. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Paradigm Press

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.

Click here to find out that this 8,788% cryptocurrency is.

About Morphic Stock (NASDAQ:MORF)

Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidate MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation is in Phase 2 clinical trials for the treatment of inflammatory bowel disease. The company's products in pipeline include Next Gen a4ß7 Inhibitors for additional potential GI indications, such as EGIDs, pouchitis, etc.; avß8 for the treatment of Myelofibrosis and solid tumor; and fibronectin integrin for pulmonary hypertensive. In addition, it has a license agreement with Janssen to discover and develop novel integrin therapeutics; collaboration agreement with Schrödinger for integrin targets; and license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. Morphic Holding, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

MORF Stock Price History

30 days | 90 days | 365 days | Advanced Chart

MORF Stock News Headlines

April 2, 2024 | prnewswire.com

Ademi LLP Investigates Claims of Securities Fraud against Morphic Holding, Inc.

March 26, 2024 | businesswire.com

Morphic Holding, Inc. (MORF) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

April 20, 2024 | Paradigm Press (Ad)

Biden replacement revealed?

A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.

March 22, 2024 | insidermonkey.com

Billionaire Steve Cohen and Insiders are Buying These 5 Stocks

March 19, 2024 | finanznachrichten.de

Morphic Therapeutic: Morphic Appoints Dr. Simon Cooper as Chief Medical Officer

March 19, 2024 | markets.businessinsider.com

Morphic Appoints Simon Cooper As Chief Medical Officer

March 19, 2024 | globenewswire.com

Morphic Appoints Dr. Simon Cooper as Chief Medical Officer

March 17, 2024 | finance.yahoo.com

MORF Jul 2024 17.500 put

April 20, 2024 | Paradigm Press (Ad)

Biden replacement revealed?

A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.

March 16, 2024 | finance.yahoo.com

MORF Apr 2024 50.000 call

March 16, 2024 | finance.yahoo.com

MORF Apr 2024 20.000 put

March 16, 2024 | finance.yahoo.com

MORF Jul 2024 40.000 call

March 11, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: MoonLake Immunotherapeutics (MLTX) and Morphic Holding (MORF)

March 8, 2024 | markets.businessinsider.com

Morphic Holding: Strong Financials and Promising Clinical Trials Reinforce Buy Rating

March 5, 2024 | globenewswire.com

Morphic to Participate in March Investor Conferences

March 3, 2024 | ca.finance.yahoo.com

MORF Jul 2024 30.000 call

February 26, 2024 | markets.businessinsider.com

Morphic Holding’s Strong Clinical Progress and Financial Stability Support Buy Rating

February 26, 2024 | markets.businessinsider.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Celldex (CLDX), Abbott Labs (ABT) and Morphic Holding (MORF)

February 23, 2024 | markets.businessinsider.com

Morphic Holding’s Buy Rating Affirmed on Strong Clinical and Financial Prospects

February 22, 2024 | finanznachrichten.de

Morphic Therapeutic: Morphic Announces Corporate Highlights and Financial Results for the Full Year 2023

February 22, 2024 | benzinga.com

Recap: Morphic Holding Q4 Earnings

February 22, 2024 | finance.yahoo.com

Morphic Announces Corporate Highlights and Financial Results for the Full Year 2023

February 22, 2024 | globenewswire.com

Morphic Announces Corporate Highlights and Financial Results for the Full Year 2023

February 14, 2024 | msn.com

New Strong Buy Stocks for February 14th

February 8, 2024 | finance.yahoo.com

Wall Street Analysts Think Morphic Holding, Inc. (MORF) Could Surge 57.22%: Read This Before Placing a Bet

January 18, 2024 | finance.yahoo.com

Morphic Holding Inc CEO Praveen Tipirneni Sells 13,923 Shares

January 11, 2024 | tmcnet.com

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Morphic Holding, Inc. (MORF) on Behalf of Investors

See More Headlines

Receive MORF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Morphic and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/22/2024
Today: 4/20/2024
Next Earnings (Estimated): 4/23/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:MORF
CUSIP: N/A
CIK: 1679363
Web: www.morphictx.com
Phone: (781) 996-0955
Fax: N/A
Employees: 121
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $61.00
High Stock Price Target: $80.00
Low Stock Price Target: $33.00
Potential Upside/Downside: +117.9%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.67
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.49)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-152,100,000.00
Net Margins: N/A
Pretax Margin: -29,119.96%
Return on Equity: -23.62%
Return on Assets: -22.90%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 28.94
Quick Ratio: 28.94

Sales & Book Value

Annual Sales: $520,000.00
Price / Sales: 2,693.50
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $14.01 per share
Price / Book: 2.00

Miscellaneous

Outstanding Shares: 50,040,000
Free Float: 35,977,000
Market Cap: $1.40 billion
Optionable: Optionable
Beta: 1.42

7 Stocks to Own Before the 2024 Election

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

Dr. Bruce N. Rogers Ph.D. (Age 55)
President & Interim Principal Executive Officer
Comp: $787.88k
Dr. Timothy A. Springer Ph.D. (Age 76)
Founder, Independent Director & Member of Scientific Advisory Board
Comp: $40k
Dr. Marc Schegerin M.B.A. (Age 48)
M.D., CFO & COO
Comp: $722.38k
Dr. Praveen P. Tipirneni M.D. (Age 55)
CEO, MD & Director (Leave of Absence)
Comp: $991.33k
Mr. Robert E. Farrell Jr. (Age 59)
CPA, Senior VP of Finance & Chief Accounting Officer
Dr. Blaise Lippa Ph.D.
Chief Scientific Officer
Mr. William D. DeVaul Esq. (Age 53)
General Counsel & Secretary
Comp: $601.44k
Mr. Aaron Pelta
Senior Vice President of Business & Corporate Development
Ms. Joanne Gibbons
Senior Vice President of Regulatory Affairs
Dr. Simon Cooper MBBS (Age 54)
Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

MORF Stock Analysis - Frequently Asked Questions

Should I buy or sell Morphic stock right now?: 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Morphic in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" MORF shares.
View MORF analyst ratings or view top-rated stocks.
What is Morphic's stock price target for 2024?: 6 analysts have issued 1 year price objectives for Morphic's shares. Their MORF share price targets range from $33.00 to $80.00. On average, they predict the company's stock price to reach $61.00 in the next year. This suggests a possible upside of 117.9% from the stock's current price.
View analysts price targets for MORF or view top-rated stocks among Wall Street analysts.
How have MORF shares performed in 2024?: Morphic's stock was trading at $28.88 at the start of the year. Since then, MORF stock has decreased by 3.1% and is now trading at $27.99.
View the best growth stocks for 2024 here.
When is Morphic's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 23rd 2024.
View our MORF earnings forecast.
How were Morphic's earnings last quarter?: Morphic Holding, Inc. (NASDAQ:MORF) issued its earnings results on Thursday, February, 22nd. The company reported ($0.94) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.89) by $0.05.

What ETFs hold Morphic's stock?: ETFs with the largest weight of Morphic (NASDAQ:MORF) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO).First Trust Small Cap Growth AlphaDEX Fund (FYC).
What other stocks do shareholders of Morphic own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Morphic investors own include Fulcrum Therapeutics (FULC), Akero Therapeutics (AKRO), AVEO Pharmaceuticals (AVEO), Atreca (BCEL), CymaBay Therapeutics (CBAY), Chiasma (CHMA), Clovis Oncology (CLVS), Gritstone bio (GRTS), Idera Pharmaceuticals (IDRA) and Kaleido Biosciences (KLDO).
When did Morphic IPO?: Morphic (MORF) raised $75 million in an IPO on Thursday, June 27th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Jefferies, Cowen, BMO Capital Markets and Wells Fargo Securities acted as the underwriters for the IPO.
How do I buy shares of Morphic?: Shares of MORF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MORF) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Morphic (MORF) Stock Price, News & Analysis

Morphic MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Morphic Stock (NASDAQ:MORF)

MORF Stock Price History

MORF Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

MORF Stock Analysis - Frequently Asked Questions

Overall MarketRank^™